• 1. An aptamer-based keypad lock system?
  Yaqing Liu,Jiangtao Ren,Jing Li,Jiyang Liu,Erkang Wang Chem. Commun., 2012,48, 802-804
• 2. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 3. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 4. An alumina stabilized graphene oxide wrapped SnO2 hollow sphere LIB anode with improved lithium storage?
  Xiang Liu,Qian Sun,A. B. Djuri?i?,Maohai Xie,Baohu Dai,Jinyao Tang,Charles Surya,Changzhong Liao,Kaimin Shih RSC Adv., 2015,5, 100783-100789
• 5. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782

Introduction to 3-(5-bromo-2-chlorophenyl)-1,2-oxazol-5-amine (CAS No. 1096829-64-9)

3-(5-bromo-2-chlorophenyl)-1,2-oxazol-5-amine is a heterocyclic organic compound that has garnered significant attention in the field of pharmaceutical chemistry due to its versatile structural framework and potential biological activities. This compound, identified by the CAS number 1096829-64-9, belongs to the oxazole class of molecules, which are known for their broad spectrum of pharmacological properties. The presence of both bromo and chloro substituents on the aromatic ring enhances its reactivity, making it a valuable intermediate in the synthesis of more complex molecules.

The structural motif of 3-(5-bromo-2-chlorophenyl)-1,2-oxazol-5-amine consists of an oxazole ring linked to a phenyl group, which is further functionalized with bromine and chlorine atoms at the 5th and 2nd positions, respectively. This specific arrangement of substituents imparts unique electronic and steric properties to the molecule, influencing its interactions with biological targets. The oxazole ring itself is a six-membered heterocycle containing one oxygen atom and two nitrogen atoms, which are critical for its role in various biochemical processes.

In recent years, there has been a surge in research focused on developing novel therapeutic agents derived from oxazole derivatives. The combination of halogenated aromatic rings with heterocyclic cores has been particularly fruitful in generating compounds with enhanced binding affinity and selectivity. 3-(5-bromo-2-chlorophenyl)-1,2-oxazol-5-amine represents a promising candidate in this category, as it combines the advantageous features of both halogenated phenyl groups and the bioactive oxazole core.

One of the most compelling aspects of 3-(5-bromo-2-chlorophenyl)-1,2-oxazol-5-amine is its potential as a scaffold for drug discovery. The bromo and chloro substituents make it an excellent precursor for further functionalization via cross-coupling reactions such as Suzuki-Miyaura or Buchwald-Hartwig couplings. These reactions allow for the introduction of diverse pharmacophores at various positions on the aromatic ring, enabling the creation of libraries of compounds with tailored biological activities.

Recent studies have highlighted the importance of halogenated oxazole derivatives in medicinal chemistry. For instance, compounds analogous to 3-(5-bromo-2-chlorophenyl)-1,2-oxazol-5-amine have shown promise in inhibiting certain kinases and enzymes implicated in cancer progression. The halogen atoms not only enhance the metabolic stability of these molecules but also improve their binding interactions with target proteins. This has led to increased interest in developing halogenated oxazoles as lead compounds for oncology applications.

The synthesis of 3-(5-bromo-2-chlorophenyl)-1,2-oxazol-5-amine typically involves multi-step organic transformations starting from commercially available precursors. The process often begins with the formation of the oxazole ring through cyclization reactions between β-diketones or β-ketoesters with appropriate nitrogen-containing compounds. Subsequent halogenation steps introduce the bromo and chloro substituents onto the phenyl ring using reagents such as N-bromosuccinimide (NBS) or phosphorus oxychloride (POCl?).

The choice of synthetic route can significantly impact the yield and purity of 3-(5-bromo-2-chlorophenyl)-1,2-oxazol-5-am ine, making optimization a critical step in its production. Advances in catalytic methods have enabled more efficient and scalable syntheses, reducing costs and improving accessibility for research purposes. For example, palladium-catalyzed cross-coupling reactions have been successfully employed to construct complex aryl ethers and other functionalized derivatives from simpler starting materials.

The pharmacological profile of 3-(5-bromo -2-chlorophenyl)-1 , 2 -ox az ol - 5 -a mine is still under active investigation, but preliminary data suggest that it may exhibit inhibitory activity against several enzymes relevant to inflammation and cell proliferation. The oxazole core is known to interact with various biological targets due to its ability to form hydrogen bonds and π-stacking interactions. Additionally, the halogen atoms can modulate these interactions by influencing electronic distribution across the molecule.

In conclusion,3-( 5 -bromo - 2 -chlorophen yl ) - 1 , 2 -ox az ol - 5 -a mine (CAS No. 10968 29 -64 -9) is a structurally interesting compound with significant potential in pharmaceutical research. Its unique combination of functional groups makes it a valuable building block for synthesizing novel therapeutic agents. As our understanding of molecular interactions continues to evolve,3-( 5 -bromo - 2 -chlorophen yl ) - 1 , 2 -ox az ol - 5 -a mine is likely to play an important role in future drug discovery efforts across multiple therapeutic areas.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)